At the time of writing, Caris Life Sciences Inc [CAI] stock is trading at $28.86, up 1.91%. An important factor to consider is whether the stock is rising or falling in short-term value. The CAI shares have gain 13.04% over the last week, with a monthly amount drifted -1.20%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Caris Life Sciences Inc [NASDAQ: CAI] stock has seen the most recent analyst activity on December 02, 2025, when Canaccord Genuity initiated its Hold rating and assigned the stock a price target of $28. Previously, Wolfe Research started tracking the stock with Outperform rating on July 14, 2025, and set its price target to $32. On July 14, 2025, TD Cowen initiated with a Buy rating and assigned a price target of $32 on the stock. JP Morgan started tracking the stock assigning an Overweight rating and suggested a price target of $31 on July 14, 2025. Guggenheim initiated its recommendation with a Buy and recommended $32 as its price target on July 14, 2025. Evercore ISI started tracking with an Outperform rating for this stock on July 14, 2025, and assigned it a price target of $33. In a note dated July 14, 2025, Citigroup initiated a Buy rating and provided a target price of $34 on this stock.
For the past year, the stock price of Caris Life Sciences Inc fluctuated between $22.86 and $42.50. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Caris Life Sciences Inc [NASDAQ: CAI] shares were valued at $28.86 at the most recent close of the market. An investor can expect a potential return of 21.28% based on the average CAI price forecast.
Analyzing the CAI fundamentals
According to Caris Life Sciences Inc [NASDAQ:CAI], the company’s sales were 649.06M for trailing twelve months, which represents an 113.38% jump. Gross Profit Margin for this corporation currently stands at 0.34% with Operating Profit Margin at 0.1%, Pretax Profit Margin comes in at -0.35%, and Net Profit Margin reading is -0.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is 0.39 and Total Capital is 0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 27.85 points at the first support level, and at 26.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.48, and for the 2nd resistance point, it is at 30.11.
Ratios To Look Out For
It is important to note that Caris Life Sciences Inc [NASDAQ:CAI] has a current ratio of 9.93. On the other hand, the Quick Ratio is 9.36, and the Cash Ratio is 8.77. Considering the valuation of this stock, the price to sales ratio is 12.55, the price to book ratio is 17.02.
Transactions by insiders
Recent insider trading involved Denton John Russel, that happened on Nov 07 ’25 when 4184.0 shares were purchased. President, Spetzler David Baxley completed a deal on Nov 07 ’25 to buy 400.0 shares. Meanwhile, Denton John Russel bought 7500.0 shares on Jun 20 ’25.
